Mineralys Therapeutics insider plans stock sale

Mineralys Therapeutics, Inc. filed a notice for the potential sale of its common stock by an affiliate.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. filed a notice for the potential sale of its common stock by an affiliate. The filing covers 7,438 shares of common stock, to be sold through Merrill Lynch on July 21, 2026, following the exercise of employee stock options via a broker-assisted cashless exercise. The covered shares have an aggregate market value of $199,884.80 based on the information provided.

The filing also lists a prior sale by Eric Warren of 104,124 shares of common stock on June 26, 2026 for total proceeds of $2,696,321.98 during the past three months.

Key Figures

Shares to be sold: 7,438 shares Aggregate market value: $199,884.80 Past 3-month shares sold: 104,124 shares +2 more

5 metrics

Shares to be sold 7,438 shares Common stock covered for potential sale on July 21, 2026

Aggregate market value $199,884.80 Value of 7,438 common shares covered by the new notice

Past 3-month shares sold 104,124 shares Common stock sold on June 26, 2026

Past 3-month sale proceeds $2,696,321.98 Proceeds from June 26, 2026 sale of 104,124 shares

Planned sale date 07/21/2026 Scheduled date for sale of 7,438 shares

Key Terms

Form 144, Exercise of employee stock options, Broker assisted cashless exercise

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Exercise of employee stock options financial

"Exercise of employee stock options | Mineralys Therapeutics, Inc."

Broker assisted cashless exercise financial

"Broker assisted cashless exercise"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Mineralys Therapeutics (MLYS) disclose in this Form 144 filing?

Mineralys Therapeutics discloses a planned sale of 7,438 shares of common stock by an affiliate on July 21, 2026 after an employee stock option exercise, along with a previously completed sale during the last three months.

How many Mineralys Therapeutics (MLYS) shares are covered by the new sale notice?

The notice covers 7,438 shares of common stock of Mineralys Therapeutics, Inc. These shares relate to an exercise of employee stock options and are to be sold through Merrill Lynch in a broker-assisted cashless transaction.

What is the aggregate market value of the MLYS shares in the planned sale?

The planned sale involves shares with an aggregate market value of $199,884.80. This value applies to the 7,438 shares of common stock that may be sold through Merrill Lynch on July 21, 2026.

What prior Mineralys Therapeutics (MLYS) stock sale is disclosed for the past three months?

The filing reports that on June 26, 2026, 104,124 shares of Mineralys Therapeutics common stock were sold for total proceeds of $2,696,321.98. This transaction is listed as a sale during the past three months.

Who is the selling security holder in the recent MLYS Form 144 disclosure?

The filing identifies Eric Warren, with a Radnor, Pennsylvania address, as the related party. The document associates him with a June 26, 2026 sale of 104,124 common shares for $2,696,321.98 and the new notice to sell 7,438 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/21/2026 - 04:11 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001916048
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Warren Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	7438	199884.80	82498101	07/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/21/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			7438	07/21/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Warren 150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PA 19087	Common Stock	06/26/2026	104124	2696321.98

144: Remarks and Signature

Remarks
Date of Notice	07/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Eric Warren
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)